Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04791774 |
Other study ID # |
NL60452.068.17 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
March 27, 2018 |
Est. completion date |
November 30, 2019 |
Study information
Verified date |
March 2021 |
Source |
Maastricht University Medical Center |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
In the current study, we willquantitate the difference in digestion and absorption kinetics
of dietary whole protein versus free amino acids in vivo in critically ill patients admitted
to the intensive care unit suffering from malabsorption. 16 adult, mechanically ventilated
ICU patients with clinical signs of malabsorption (faecal weight >350 g/day) will be
included. All patients will receive a primed continuous intravenous infusion of
L-[ring2H5]-phenylalanine and L-[3,5-2H2]-Tyrosine for the duration of the study period.
After reaching an isotopic steady state (1.5 hours), patients will receive either [1-13C]-
phenylalanine labelled milk protein or free amino acids with an identical constitution and
[1-13C]-phenylalanine.
Main study endpoint will be the splanchnic extraction of phenylalanine, calculated from
systemic [1-13C]- and L-[ring2H5]-phenylalanine enrichment.
Description:
Background of the study:
The importance of the provision of sufficient protein in critical illness is increasingly
recognized. Protein malabsorption seems to be an underestimated but substantial problem in
critically ill patients, limiting the amount of this important nutrient that actually becomes
available within the systemic circulation. Among several contributors to malabsorption in
critical illness, exocrine pancreatic insufficiency has recently emerged as a regularly
occurring phenomenon during critical illness. Pancreatic insufficiency could lead to reduced
digestion and subsequent uptake of enteral provided proteins. A proposed solution to this
problem could be the use of elementary feeds containing free amino acids instead of whole
protein. Due to the lack of easy applicable and reproducible tests for protein malabsorption
the true efficacy of these feeds is still unknown. We hypothesize that enteral nutrition
containing free amino acids leads to higher systemic levels of amino acids and will therefore
increase the amount of dietary amino acids available for protein synthesis.
Objective of the study:
To quantitate the difference in digestion and absorption kinetics of dietary whole protein
versus free amino acids in vivo in patients admitted to the ICU suffering from malabsorption.
Study design:
Randomized, single-blind controlled, single-centre, intervention study.
Study population:
16 adult, mechanically ventilated ICU patients with clinical signs of malabsorption (faecal
weight >350 g/day).
Intervention:
Normal enteral nutrition will be ceased 8 hours before the start of study participation. All
patients will receive a primed continuous intravenous infusion of L-[ring2H5]-phenylalanine
and L-[3,5-2H2]-Tyrosine for the duration of the study period. After reaching an isotopic
steady state (1.5 hours), patients will receive either [1-13C]- phenylalanine labelled milk
protein or free amino acids with an identical constitution and [1-13C]-phenylalanine.
Primary study parameters/outcome of the study:
Main study endpoint will be the splanchnic extraction of phenylalanine, calculated from
systemic [1-13C]- and L-[ring2H5]-phenylalanine enrichment.
Secundary study parameters/outcome of the study:
Secondary endpoints include the impact of enteral nutrition on whole body protein balance,
glucose and insulin concentrations and faecal energy and protein loss as a measure of
malabsorption.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness:
Total study participation will take 16 hours, including 8 hours of fasting. Arterial blood
samples will be collected regularly, with 50 ml of blood being sampled in total, amounting to
a maximum of 1.0% of total circulating volume. All infusions, as well as blood sample
collection, will be performed through indwelling catheters necessary for normal ICU
treatment, meaning no lines or nasogastric tubes will have to be placed for the purposes of
the study. Both isotopically labelled protein and free amino acids have been proven safe for
use in humans and carry no harmful risks for the study participant. Changes in protein
digestion, absorption and metabolism are specific to critical illness and their impact on the
clinical condition and recovery of patients is severe. Investigating new strategies to
modulate these effects are therefore essential, but require experimental studies in a
vulnerable population. The risks in the present study are minimal whereas the results could
help improve nutritional management in the intensive care.